Wegovy and Ozempic are the same drug, semaglutide, made by the same company, Novo Nordisk. The core difference is what they’re approved to treat: Ozempic is for type 2 diabetes, while Wegovy is for weight management. That single distinction ripples out into different doses, different pen designs, different insurance coverage, and different price experiences for patients.
Same Drug, Different Approvals
Both medications contain semaglutide, a compound that mimics a gut hormone called GLP-1. It slows digestion, reduces appetite, and helps regulate blood sugar. The FDA approved them for distinct purposes, though.
Ozempic is approved for managing type 2 diabetes, improving kidney and cardiovascular health in adults with type 2 diabetes and chronic kidney disease, and reducing cardiovascular risk in adults with type 2 diabetes and heart disease. It is specifically a diabetes medication.
Wegovy has a broader set of approvals centered on weight and its complications: weight management in adults and children 12 and older, treatment of a form of fatty liver disease with moderate or advanced scarring, and cardiovascular risk reduction in adults with obesity or overweight who also have heart disease. In the SELECT trial, Wegovy’s higher dose reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo in people with existing heart disease and a BMI of 27 or higher who did not have diabetes.
Dosing Differences
Because Wegovy targets weight loss and Ozempic targets blood sugar, Wegovy goes to a higher maintenance dose. Both medications are injected once a week under the skin, typically in the abdomen, thigh, or upper arm.
Ozempic tops out at 2.0 mg per week. Most patients start at 0.25 mg, move to 0.5 mg after four weeks, and then increase to 1.0 mg or 2.0 mg based on how well their blood sugar responds. Wegovy’s maintenance dose is 2.4 mg per week. The climb is more gradual: patients typically move through 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg over about 16 weeks before reaching the full 2.4 mg dose. Each step lasts four weeks, giving the body time to adjust and minimizing nausea.
How the Pens Work
The injection pens look similar but function differently in a way that matters for daily life. Ozempic pens are multi-dose: you attach a new disposable needle before each injection, dial up your prescribed dose, and use the same pen for four or eight weekly injections depending on your strength. Wegovy pens are single-use. Each pen comes with the needle already attached, delivers one fixed dose, and gets discarded after that single injection. Wegovy’s design is simpler in the moment (no needle attachment, no dose dialing), but you go through more pens.
Weight Loss and Blood Sugar Results
Ozempic was studied primarily for blood sugar control in the SUSTAIN clinical trials. At the 1.0 mg dose, patients with type 2 diabetes saw their HbA1c (a measure of average blood sugar over roughly three months) drop by about 1.5 to 1.8 percentage points, which is a substantial improvement. Weight loss happened too, but as a secondary benefit. In one trial, patients on semaglutide 1.0 mg lost an average of 5.8 kg (about 13 pounds) over 30 weeks, compared to 1.9 kg on a competing diabetes drug. The higher 2.0 mg dose produced slightly more weight loss, averaging 6.9 kg (about 15 pounds).
Wegovy was studied specifically for weight management in the STEP trials, using the higher 2.4 mg dose in people with obesity or overweight. Those trials showed average body weight reductions of roughly 15% over 68 weeks, significantly more than what Ozempic’s lower doses produce. The difference comes down to dose: more semaglutide means more appetite suppression and more weight loss, which is why Wegovy was formulated to go higher.
Side Effects Are Largely the Same
Since the active ingredient is identical, the side effect profile overlaps almost completely. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during the dose-escalation phase and improve as your body adjusts. Wegovy’s higher maintenance dose can mean more persistent GI symptoms for some people, though the gradual titration schedule is designed to reduce that.
Both carry the same boxed warning about thyroid tumors. In animal studies, semaglutide caused thyroid tumors in rodents. Neither Wegovy nor Ozempic should be used by anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Both are also contraindicated if you’ve had a serious allergic reaction to semaglutide.
Insurance and Cost
This is where the practical difference hits hardest for most people. Ozempic, as a diabetes drug, is covered by most insurance plans when prescribed for type 2 diabetes. Getting coverage is relatively straightforward if you have a diabetes diagnosis.
Wegovy’s path to coverage is far more complicated. Most private insurance companies and federal health programs do not cover weight-loss drugs. Medicare has been explicitly prohibited by law from covering weight-loss treatments since 2003. Without insurance, either medication costs $1,000 or more per month out of pocket. Some private insurers do cover Wegovy, but they often impose strict eligibility requirements: a formal obesity diagnosis, evidence of weight-related health conditions, or limits on how long they’ll pay for treatment.
This coverage gap is a major reason some people with obesity end up prescribed Ozempic off-label for weight loss. Doctors can legally prescribe it that way, and a diabetes-drug copay is often far more affordable than paying out of pocket for Wegovy. The trade-off is a lower maximum dose (2.0 mg vs. 2.4 mg) and the possibility that an insurer could deny coverage if the prescription doesn’t match a diabetes diagnosis.
Storage
Both medications should be stored in the refrigerator before use. Once out of the fridge, they diverge. An Ozempic pen that’s been removed from refrigeration (or exposed to temperatures above 46°F) can be used for up to 56 days, which makes sense since it’s a multi-dose pen you’ll use over several weeks. Wegovy pens can be kept at room temperature (46°F to 86°F) for up to 28 days before the cap is removed, but since each pen is single-use, storage duration matters less in practice. You use it once and throw it away.
Which One You’ll Be Prescribed
Your diagnosis determines which medication a doctor will prescribe. If you have type 2 diabetes, Ozempic is the standard choice, and any weight loss is a welcome bonus. If your primary concern is weight management without diabetes, Wegovy is the FDA-approved option. Some people with type 2 diabetes and obesity could potentially benefit from Wegovy’s higher dose and cardiovascular approval, and a doctor might consider switching them, especially if cardiovascular risk reduction is a priority. The conversion is straightforward: a patient already on Ozempic 2.0 mg for at least four weeks can move directly to Wegovy 2.4 mg without repeating the full titration.
In short, these are two packaging and dosing strategies for the same molecule. The version you get depends on what condition is being treated, what your insurance will pay for, and how much semaglutide your doctor thinks you need.